Abstract:This study introduces on‐line ultra‐performance liquid chromatography (UPLC) and multi‐mode fluorescence spectroscopy (MMFS) as innovative analytical technologies for characterizing co‐formulated monoclonal antibodies (mAbs). By measuring critical quality attributes (CQAs) efficiently, these methods significantly reduce analytical turnaround time and enhance manufacturing processes. On‐line UPLC offers automated and precise measurements, while MMFS provides a rapid, cost‐effective alternative for simultaneous CQA assessment. Together, they support the pharmaceutical industry's need for expedited clinical development and improved product quality in biopharmaceutical manufacturing. Characterizing co‐formulated monoclonal antibodies (mAbs) poses significant challenges in the pharmaceutical industry. Due to the high structural similarity of the mAbs, traditional analytical methods, compounded by the lengthy method development process, hinder product development and manufacturing efficiency. There is increasing critical need in the pharmaceutical industry to streamline analytical approaches, minimizing time and resources, ensuring a rapid clinical entry and cost‐effective manufacturing. This study investigates the application of process analytical technologies (PAT) to address such challenges. Our investigation introduces two complementary technologies, on‐line ultra‐performance liquid chromatography (online UPLC) and multimode fluorescence spectroscopy (MMFS), as potential PAT tools tailored for characterizing critical quality attributes (CQA) in co‐formulated mAb products. Specifically, the CQAs under evaluation include the total protein concentration of the mAbs within the co‐formulation and the ratio of mAb A to mAb B. Online UPLC enables direct and automated measurement of the CQAs through physical separation, while MMFS determines them in a non‐destructive and more swift manner based on chemometric modeling. We demonstrate these technologies' comparable performance to conventional methods, alongside substantial benefits such as reduced analytical turnaround time and decreased laboratory efforts. Ultimately, integrating them as innovative PAT tools expedites the delivery of therapeutic solutions to patients and enhances manufacturing efficiency, aligning with the imperative for swift translation of scientific discoveries into clinical benefits.

A Hydrophobic Interaction Chromatography Method Suitable for Quantitating Individual Monoclonal Antibodies Contained in Co-Formulated Drug Products.

Separation and purification of anti-HER2 monoclonal antibody with hydrophobic charge-induction chromatography

Integration of Expanded Bed Adsorption and Hydrophobic Charge-Induction Chromatography for Monoclonal Antibody Separation

Offline Coupling of Hydrophobic Interaction Chromatography–Capillary Zone Electrophoresis for Monitoring Charge‐Based Heterogeneity of Recombinant Monoclonal Antibodies

Integration of protein L-immobilized epoxy magnetic bead capture with LC-MS/MS for therapeutic monoclonal antibody quantification in serum

Detection and quantitation of host cell proteins in monoclonal antibody drug products using automated sample preparation and data-independent acquisition LC-MS/MS

Optimized Sample Preparation and Data Processing of Data-Independent Acquisition Methods for the Robust Quantification of Trace-Level Host Cell Protein Impurities in Antibody Drug Products

Monitoring Removal of Hole-Hole Homodimer by Analytical Hydrophobic Interaction Chromatography in Purifying a Bispecific Antibody.

Preparation and Evaluation of Dextran-Grafted Agarose Resin for Hydrophobic Charge-Induction Chromatography.

Analysis of Host Cell Proteins in Monoclonal Antibody Therapeutics Through Size Exclusion Chromatography

Post-Column Denaturation-Assisted Native Size-Exclusion Chromatography-Mass Spectrometry for Rapid and In-Depth Characterization of High Molecular Weight Variants in Therapeutic Monoclonal Antibodies.

Improved Host Cell Protein Analysis in Monoclonal Antibody Products through Molecular Weight Cutoff Enrichment

Simple and Sensitive Method for Deep Profiling of Host Cell Proteins in Therapeutic Antibodies by Combining Ultra-Low Trypsin Concentration Digestion, Long Chromatographic Gradients, and BoxCar Mass Spectrometry Acquisition.

A New Tool for Monoclonal Antibody Analysis

Deciphering the High Viscosity of a Therapeutic Monoclonal Antibody in High Concentration Formulations by Microdialysis-Hydrogen/Deuterium Exchange Mass Spectrometry.

Modeling the behavior of monoclonal antibodies on hydrophobic interaction chromatography resins

A novel approach to monitor clearance of host cell proteins associated with monoclonal antibodies

Implemention of Innovative Process Analytical Technologies to Characterize Critical Quality Attributes of Co‐Formulated Monoclonal Antibody Products

Coupling Mixed-Mode Size Exclusion Chromatography with Native Mass Spectrometry for Sensitive Detection and Quantitation of Homodimer Impurities in Bispecific IgG.

A Combination of FAIMS, Protein A Depletion, and Native Digest Conditions Enables Deep Proteomic Profiling of Host Cell Proteins in Monoclonal Antibodies.

High throughput multidimensional liquid chromatography approach for online protein removal and characterization of polysorbates and poloxamer in monoclonal antibody formulations